A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer


Full Title

Sulfonylurea Safety and Effectiveness (SUSS) for Patients with Hyperglycemia and Pancreatic Ductal Adenocarcinoma: A Pragmatic Clinical Trial and Accompanying Retrospective Review


Hyperglycemia (high blood sugar) is very common in people with pancreatic cancer. Hyperglycemia happens when your body does not make enough of the insulin hormone, or it may not use insulin the way it should. In people with pancreatic cancer, the cancer sends signals to the pancreas to tell it to stop producing enough insulin.

There are various drugs used to treat hyperglycemia. Glipizide may be especially useful because it tells the pancreas to make more insulin, which reduces excess blood sugar. At Memorial Sloan Kettering Cancer Center, glipizide is a standard drug used to treat hyperglycemia in people with pancreatic cancer.

In this study, researchers are assessing glipizide for treating hyperglycemia in people with pancreatic cancer. If you join this study, you will wear a continuous glucose monitor to check your blood sugar. This is a sensor you wear on your arm that tracks your sugar levels continuously.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have metastatic pancreatic cancer and hyperglycemia.
  • Be willing to wear the continuous glucose monitor, which also requires you to have wifi and a cell phone.
  • Not be obese (body mass index under 30).
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. James Flory’s office at 646-608-2684.




Phase II (phase 2)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID